P/E ratio for Alaunos Therapeutics (TCRT)
P/E ratio as of May 2024 (TTM): -8.25
According to Alaunos Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.25. At the end of 2022 the company had a P/E ratio of -3.61.
P/E ratio history for Alaunos Therapeutics from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.61 | 22.58% |
| 2021 | -2.95 | -54.41% |
| 2020 | -6.46 | -5.54% |
| 2019 | -6.84 | -425.57% |
| 2018 | 2.10 | -127.41% |
| 2017 | -7.67 | 89.16% |
| 2016 | -4.05 | -50.74% |
| 2015 | -8.23 | -49.69% |
| 2014 | -16.4 | 144.95% |
| 2013 | -6.68 | 95.81% |
| 2012 | -3.41 | -21.13% |
| 2011 | -4.32 | -33.2% |
| 2010 | -6.47 | -27.84% |
| 2009 | -8.97 | 1755.8% |
| 2008 | -0.4833 | -80.61% |
| 2007 | -2.49 | -37.78% |
| 2006 | -4.01 | 7680.36% |
| 2005 | -0.0515 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.